International › Australia · Last reviewed 2026-05-16

Australia

Summary

In Australia, a team at the Royal Children's Hospital Melbourne published the Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents in 2018. Until 2017 court authorisation was required for Stage 2 treatment with cross-sex hormones (Re Jamie, Re Kelvin). In 2025 Queensland paused the start of puberty suppression and hormone therapy for children and adolescents in public hospitals, and on 19 December 2025 it extended that pause until 2031 (source).

1. Royal Children's Hospital Melbourne 2018 guideline

The Royal Children's Hospital Melbourne (RCH) published the Australian Standards of Care and Treatment Guidelines for Transgender and Gender Diverse Children and Adolescents in 2018. According to the authors, the recommendations rest on available empirical evidence and clinician consensus and take an affirmative approach, and the timing of medical transition depends on the adolescent's capacity and competence, the time on puberty suppression, coexisting problems and family support rather than on chronological age (source).1

2. Family Court — Re Jamie and Re Kelvin

Until 2017 court authorisation was required for Stage 2 treatment (cross-sex hormones) under Re Jamie (2013). In Re Kelvin (2017) the Full Court of the Family Court of Australia ruled that Stage 2 treatment no longer requires court authorisation; court involvement is still needed where parents and doctors, or the parents with each other, disagree (source). See /debate/legal-cases/.2

3. Queensland pause (2025)

In 2025 the Queensland government paused the start of puberty suppression and hormone therapy for children and adolescents in public hospitals. On 19 December 2025 it extended the pause until 2031, when the results of the UK PATHWAYS trial are expected, after an independent review led by Professor Ruth Vine found the evidence base for these treatments limited, with little evidence on long-term risks or benefits. Existing patients continue their treatment (source).3

See also

Footnotes

  1. Telfer MM, Tollit MA, Pace CC, Pang KC. Australian standards of care and treatment guidelines for transgender and gender diverse children and adolescents. Med J Aust. 2018;209:132–136.
  2. Re Kelvin [2017] FamCAFC 258.
  3. Queensland Government, Minister for Health and Ambulance Services. Statement on the pause on hormone therapies for children and adolescents, 19 December 2025.
  4. D'Angelo R, et al. One size does not fit all: in support of psychotherapy for gender dysphoria. Arch Sex Behav. 2021;50(1):7–16.